Jatenzo Cost in Colorado 2026: Cash Price, Insurance, Medicaid, and Compounding Options

What Is Jatenzo and Why Does Price Vary by State

Jatenzo is the first FDA-approved oral testosterone product in the United States designed to be absorbed via intestinal lymphatic transport, bypassing first-pass hepatic metabolism. The active ingredient is testosterone undecanoate, a fatty-acid ester of testosterone that requires co-ingestion with dietary fat for adequate absorption. Each capsule comes in three strengths: 158 mg, 198 mg, and 237 mg, taken twice daily. Tolmar Pharmaceuticals holds the NDA (210268) and sets the wholesale acquisition cost that cascades into retail sticker prices across every state, including Colorado.

Price varies by state primarily because pharmacy benefit manager (PBM) contracts, state Medicaid formularies, and local dispensing fees differ. Colorado's large insurer mix, including Anthem BlueCross, Cigna, Kaiser Permanente, and the state's Medicaid program Health First Colorado, each apply their own coverage rules. A Colorado cash-pay patient and an insured patient in Denver may face costs separated by hundreds of dollars per month for the identical 60-capsule supply. FDA NDA 210268 approval confirms the labeled indication: adult males with hypogonadism due to primary or secondary causes.

The key registration trial, Swerdloff et al. (J Clin Endocrinol Metab 2020, N=166), showed that 87% of men treated with oral testosterone undecanoate achieved total testosterone levels within the eugonadal range (300 to 1 to 000 ng/dL) over 120 days of twice-daily dosing [1]. That efficacy data anchored the FDA's 2019 approval and remains the basis for coverage arguments made to insurers today. The full FDA prescribing information lists hypertension risk as the only REMS-level concern, which can also affect insurer tier placement.

Jatenzo Cash Price in Colorado 2026

The cash-pay price for Jatenzo at Colorado retail pharmacies in 2026 is approximately $900 per month for a 60-capsule supply, regardless of strength. That figure reflects the manufacturer's wholesale acquisition cost with standard retail markup and a typical dispensing fee. GoodRx and similar discount aggregators show prices from roughly $820 to $940 across Denver, Colorado Springs, Fort Collins, Aurora, and Pueblo pharmacies, with independent pharmacies occasionally landing slightly below chain prices.

No generic oral testosterone undecanoate is FDA-approved in the United States. Andriol, the international brand of oral testosterone undecanoate, is not approved or commercially distributed domestically. That absence of generic competition explains why the cash price has remained close to the WAC floor since launch. The Endocrine Society's 2018 clinical practice guideline on male hypogonadism acknowledges cost as a real barrier to testosterone therapy adherence for uninsured and underinsured patients.

Large retail chains such as Costco Pharmacy in Colorado have historically offered slightly lower cash prices on controlled substances when customers pay out-of-pocket without insurance. Presenting a GoodRx or RxSaver coupon at independent Colorado pharmacies can reduce the cash price by 5 to 10 percent, though these coupons cannot be combined with insurance or the Tolmar savings card. PubMed data on testosterone therapy cost burden confirms that out-of-pocket cost is a leading reason men discontinue TRT within the first 6 months.

Colorado Medicaid (Health First Colorado) Coverage for Jatenzo

Health First Colorado does not cover Jatenzo for male hypogonadism in 2026. The state Medicaid formulary restricts oral testosterone undecanoate coverage to a narrow indication: adjunct therapy in adult men with type 2 diabetes who also have confirmed hypogonadism. This mirrors a national Medicaid trend where Jatenzo sits on a non-preferred or excluded tier for straightforward hypogonadism diagnoses. CMS Medicaid drug policy guidance leaves formulary decisions to individual states, explaining why coverage differs across state lines.

For a Colorado Medicaid patient who qualifies under the type 2 diabetes carve-out, a prior authorization (PA) request must document: (1) a fasting testosterone level below 300 ng/dL on two separate morning draws, (2) a confirmed type 2 diabetes diagnosis with HbA1c on file, and (3) failure or intolerance of at least one preferred testosterone formulation, typically a generic transdermal gel. Without meeting all three criteria, Medicaid will deny the PA. The American Urological Association's 2018 guideline on testosterone deficiency supports morning fasting testosterone measurement as the diagnostic standard, which aligns with what Health First Colorado reviewers expect in a PA packet.

Medicaid beneficiaries who do not meet the type 2 diabetes carve-out have three practical alternatives: apply for the Tolmar patient assistance program, seek a 503A compounded oral testosterone undecanoate, or switch to a generic topical testosterone that does carry Medicaid coverage.

Insurance Coverage for Jatenzo in Colorado: Commercial Plans

Most major commercial insurers in Colorado place Jatenzo on a non-preferred specialty tier, requiring prior authorization and sometimes step therapy. Step therapy typically means demonstrating that the patient tried and failed generic testosterone cypionate injections or a generic testosterone gel (such as testosterone 1% gel) before Jatenzo is approved. FDA guidance on testosterone products notes that all testosterone formulations carry the same general class labeling for hypogonadism, which PBMs use to justify step therapy requirements.

Anthem BlueCross BlueShield of Colorado lists Jatenzo as Tier 4 or Tier 5 on most employer-sponsored plans in 2026, translating to a 25 to 40 percent coinsurance after the deductible. For a $900 list-price drug, that means $225 to $360 per fill even after insurance processes the claim. Cigna Colorado and United Healthcare Colorado plans similarly place it in the specialty tier with coinsurance rates in the same range. A 2022 analysis in JAMA Internal Medicine found that specialty-tier TRT formulations had a 3.4-fold higher abandonment rate at pharmacy than preferred-tier generic injectables.

Kaiser Permanente Colorado operates as a closed formulary HMO. Jatenzo is not on the Kaiser standard formulary as of early 2026, meaning members generally cannot get it covered through Kaiser unless an exception is approved via the formulary exception process.

To maximize the chance of approval on any commercial plan in Colorado, the prescribing clinician should submit: morning total testosterone values below 300 ng/dL on two occasions (per Endocrine Society guidelines), LH/FSH values establishing primary or secondary hypogonadism, documentation of symptoms using the ADAM questionnaire, and a reason the patient cannot use injectable or topical alternatives (for example, needle phobia, dermatitis, or patch adhesive allergy).

The Tolmar Savings Card: How It Works in Colorado

The Tolmar savings card (also called the Jatenzo co-pay card) is the most direct cost-reduction tool available to commercially insured Colorado patients. Eligible patients pay as little as $0 per month, with Tolmar covering the remaining balance up to a defined annual maximum. For 2026, the program cap is $4,800 per calendar year per patient.

Eligibility rules are specific. The patient must have commercial insurance that covers Jatenzo (even partially). Federal and state government program beneficiaries, including Medicare Part D and Medicaid enrollees, are explicitly excluded by the card's terms of service, which reflects standard pharmaceutical co-pay card restrictions under the federal anti-kickback statute. HHS OIG guidance on co-pay assistance explains why these cards are prohibited for government-insured patients.

Enrollment takes roughly five minutes at the Tolmar patient services portal. The card functions like a secondary insurance card: the pharmacist runs the primary insurance first, then applies the Tolmar card to the remaining patient responsibility. The card works at most major Colorado retail chains and can be used at mail-order pharmacies that accept manufacturer co-pay cards. One practical limitation: if a pharmacy's PBM contract prohibits third-party co-pay cards (a practice known as "accumulator adjustment"), the Tolmar card payment will not count toward the patient's annual deductible or out-of-pocket maximum.

The table below outlines the four cost tiers a Colorado patient may land in, depending on insurance status:

| Patient Situation | Estimated Monthly Cost | |---|---| | Commercial insurance + Tolmar savings card | $0 (up to $4,800/year cap) | | Commercial insurance, no savings card | $225 to $360 (coinsurance estimate) | | Cash pay, no insurance | ~$820 to $940 | | Colorado Medicaid (qualifying type 2 diabetes PA) | $0 to $3 copay |

Compounded Oral Testosterone Undecanoate in Colorado: Legality and Cost

503A compounding pharmacies in Colorado may legally prepare oral testosterone undecanoate capsules for individual patients with a valid prescription from a licensed prescriber. This is legal under the federal Drug Quality and Security Act of 2013 and Colorado's Pharmacy Practice Act, provided the compound is not essentially a copy of a commercially available drug and meets the "office use" or individual patient requirements. FDA's guidance on 503A compounding clarifies the distinction between patient-specific 503A and bulk-manufacturing 503B outsourcing facilities.

The "essentially a copy" question is the central legal tension. Because Jatenzo is FDA-approved and commercially available, some pharmacies decline to compound oral testosterone undecanoate out of caution. Others argue that compounded testosterone undecanoate formulations differ in dose, base oil, or capsule composition from the branded product and therefore do not qualify as copies. Colorado's Board of Pharmacy has not issued a state-specific opinion letter resolving this ambiguity as of early 2026. Patients should ask their pharmacy explicitly whether the compound is prepared under 503A status and whether the pharmacist is comfortable that it does not constitute an essentially a copy of Jatenzo.

When available, compounded oral testosterone undecanoate from a Colorado 503A pharmacy typically costs between $60 and $180 per month, a substantial reduction from the $900 list price. Some telehealth platforms that operate in Colorado include compounded formulations as part of a membership fee, bringing the effective monthly cost to $0 for the medication itself. A 2021 JAMA study on compounded testosterone found that compounded testosterone products represented over 40% of all testosterone prescriptions written by independent telehealth providers, a figure driven almost entirely by cost differential.

Quality verification matters. Reputable 503A pharmacies hold PCAB accreditation or equivalent state board standing and perform potency, sterility, and dissolution testing. Ask any compounding pharmacy for a certificate of analysis on their oral testosterone undecanoate formulation before filling. USP Chapter 795 standards govern non-sterile compounding quality, including oral capsule preparations.

Telehealth Prescribing of Jatenzo in Colorado

Colorado permits telehealth prescribing of Schedule III controlled substances, which includes testosterone, provided the prescriber holds a valid Colorado medical license and an active DEA registration with Colorado jurisdiction. The Ryan Haight Online Pharmacy Consumer Protection Act of 2008 originally required an in-person evaluation before any controlled substance could be prescribed via telemedicine. DEA telemedicine rules updated in 2023 introduced special registrations that allow certain telehealth providers to prescribe Schedule III substances after a thorough synchronous audio-video evaluation, without a prior in-person visit.

In practice, Colorado-licensed telehealth platforms such as HealthRX can prescribe Jatenzo after a video consultation that includes review of two morning testosterone lab values, symptom documentation, and a blood pressure measurement (required by the FDA REMS program). The FDA REMS for Jatenzo mandates blood pressure monitoring at baseline and at 3 to 6 months because the drug raises blood pressure by a mean of 3 to 5 mmHg in clinical trials. Prescribers are required to confirm BP is below 165/100 mmHg before initiating therapy.

Telehealth prescribers in Colorado can send the Jatenzo prescription to any retail pharmacy the patient designates or to a mail-order pharmacy. This means a patient in rural Colorado, including areas like Durango, Grand Junction, or Alamosa, can access Jatenzo without driving to a specialist's office. A 2023 NEJM Catalyst analysis found that telehealth-initiated hormone therapy had equivalent 12-month adherence rates to in-person initiated therapy when patients had adequate pharmacist support.

Monitoring Requirements That Affect Total Cost of Care

Jatenzo prescribing in Colorado does not end at the pharmacy counter. The total monthly cost of therapy includes lab monitoring that adds to the out-of-pocket picture. Standard monitoring for a Colorado patient on Jatenzo includes:

Serum total testosterone at 3 to 4 hours post-dose (trough or post-dose peak per Swerdloff et al.) at weeks 4 and 8 after initiation, then every 6 months once the dose is stable. Hematocrit must be checked at baseline, 3 to 6 months, and annually, given the risk of erythrocytosis. The Endocrine Society guideline recommends stopping testosterone therapy if hematocrit exceeds 54%. PSA screening applies to men 40 and older per the same guideline: baseline PSA, then annually. Blood pressure checks are required by the FDA REMS at every visit.

A Colorado patient paying cash for labs outside a lab-bundle telehealth plan should expect roughly $80 to $150 for a testosterone panel, $20 to $40 for a CBC, and $30 to $60 for a PSA, totaling $130 to $250 per monitoring visit. Quest Diagnostics and LabCorp both operate Colorado patient service centers where self-pay patients can order these labs at discounted rates. LabCorp's testosterone testing reference ranges for adult males are 264 to 916 ng/dL using LC-MS/MS methodology, the gold-standard assay recommended by the Endocrine Society.

Patient Assistance Programs and Other Savings Strategies

Beyond the Tolmar savings card, two additional resources apply to Colorado patients who face high out-of-pocket costs.

Tolmar Patient Assistance Program (PAP): For uninsured or underinsured patients whose household income falls at or below 400% of the federal poverty level (roughly $60,240 for a single adult in 2026), Tolmar may provide Jatenzo at no cost through the PAP. Applications require proof of income, a completed prescriber form, and documentation of lack of adequate coverage. Processing takes 2 to 4 weeks. NeedyMeds.org maintains current enrollment links for the Tolmar PAP.

Colorado Indigent Care Program (CICP): CICP is a state-funded safety net that covers certain prescription costs for uninsured Coloradans who earn less than 250% of the FPL. CICP does not guarantee Jatenzo coverage but can subsidize the office visits and lab work associated with TRT monitoring, reducing total out-of-pocket cost indirectly. Colorado HCPF administers CICP with enrollment through county departments of human services.

Medicare Part D: Standard Medicare Part D plans in Colorado place Jatenzo in Tier 4 or Tier 5. In 2026, the Inflation Reduction Act cap on out-of-pocket drug spending applies: the catastrophic cap is $2,000 per year, meaning no Medicare Part D enrollee should pay more than $2,000 annually for covered drugs. Whether Jatenzo is covered on a given Part D plan's formulary depends on the specific plan. CMS Medicare Part D formulary guidance requires all Part D plans to cover at least two drugs per therapeutic category, but testosterone formulations often satisfy that requirement with cheaper injectables.

How Jatenzo Compares to Other Testosterone Options on Cost

Understanding the $900/month price in context helps patients and prescribers make informed decisions. Generic testosterone cypionate 200 mg/mL, the most common injectable form, costs roughly $30 to $80 per month for a typical 100 to 200 mg weekly dose from a Colorado pharmacy. Generic testosterone 1.62% gel (the generic of AndroGel) runs $50 to $120 per month. Testosterone pellets implanted subcutaneously every 3 to 6 months typically cost $400 to $700 per implant procedure in Colorado, translating to roughly $70 to $120 per month amortized.

Jatenzo's oral convenience carries a 7-to-15-fold price premium over injectable testosterone in the cash-pay market. A 2020 cost-effectiveness analysis in PharmacoEconomics estimated that oral testosterone undecanoate would need to demonstrate a quality-adjusted life year (QALY) gain of at least 0.12 over injectable alternatives to justify payer coverage at a $50,000/QALY willingness-to-pay threshold. The analysis found that patient-reported preference for oral administration, avoidance of injection site complications, and consistent absorption profile contributed modestly to QALY scores but did not fully close the cost-effectiveness gap for all payer types.

For patients in whom injection phobia, travel burden, or skin conditions make injectables or topicals impractical, Jatenzo's oral route is clinically meaningful. The Swerdloff 2020 trial [1] reported that 87% of subjects maintained testosterone levels between 300 and 1 to 000 ng/dL at steady state with twice-daily oral dosing, a response rate comparable to published benchmarks for injectable testosterone cypionate from Bhasin et al. NEJM 2001.